EGFR and non-small cell lung carcinoma: These drugs are highly effective in NSCLC patients harboring EGFR-activating mutations (exon 19 deletion and exon 21 L858R).74,76,77 They demonstrated a significant PFS benefit over platinum doublet chemotherapy in the clinic.